<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00905970</url>
  </required_header>
  <id_info>
    <org_study_id>HYPDYN</org_study_id>
    <secondary_id>CEIC EO-07-033</secondary_id>
    <nct_id>NCT00905970</nct_id>
  </id_info>
  <brief_title>Demonstration of the Dynamic Hypothesis of Latent Tuberculosis Infection</brief_title>
  <acronym>HYPDYN</acronym>
  <official_title>Demonstration of the Dynamic Hypothesis of Latent Tuberculosis Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Germans Trias i Pujol Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fondo de Investigacion Sanitaria</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Germans Trias i Pujol Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is traditionally considered that the development of Latent Tuberculosis Infection (LTBI)
      is due to the M. tuberculosis ability to develop a dormancy state within well-structured
      lesions (granulomas), which can remain in the lung of the host even for life. A new original
      hypothesis has been developed in the Experimental Tuberculosis Unit based on scientific
      evidence that take into account the idea that a lesion cannot be held forever, because the
      host tends to remove any lesion in order to rebuild the original parenchyma, in a healing
      process. Even if M. tuberculosis can remain in a dormant/non-replicating state for a long
      period, this is an important but not sufficient factor to explain the LTBI. The Dynamic
      Hypothesis tries to explain the existence of LTBI in spite of the healing process that could
      remove it by a constant reinfection of the host's tissue. While the &quot;Static&quot; view defends the
      induction of active TB after the reactivation of the bacilli from and old lesion; while the
      &quot;Dynamic&quot; view wants to demonstrate that there is a constant induction of new granulomas. In
      case one of these new lesions takes place in the upper lobe privileged zone, the possibility
      to induce a cavity would appear, developing an active Tuberculosis (TB).
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2009</start_date>
  <completion_date type="Anticipated">December 2011</completion_date>
  <primary_completion_date type="Anticipated">December 2011</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>QuantiFeron-Gold-In Tube method assay</measure>
    <time_frame>Every 6 months during 3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Detection of M.tuberculosis DNA and RNA in the exhaled breath condensate</measure>
    <time_frame>Once every year (every 6 months if possible), during 3 years</time_frame>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">105</enrollment>
  <condition>Latent Tuberculosis Infection</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>Patients with LTBI recently diagnosed under prophylactic chemotherapy treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <description>Patients with LTBI recently diagnosed not following any prophylactic chemotherapy treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <description>Patients with LTBI diagnosed time ago.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <description>Positive control for the Exhaled Breath condensate assay only. Patients with active TB will conform this group. The n of this group is determined, as it will only be used as a positive control to prove the bacilli's DNA can be detected in the exhaled breath condensate.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole blood collected on QuantiFeron-Gold-In Tube tubes. Exhaled breath collected on R-Tube
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Latent Tuberculosis Infected people
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  being at least 18 years old

          -  to be M.tuberculosis infected (diagnosed by a positive TST with or without a positive
             result in the QuantiFeron-TB-Gold In tube assay)

        Exclusion Criteria:

          -  active TB

          -  individuals not willing to participate in the study and or not willing to sign the
             informed consent form

          -  individuals not able to decide their participation in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pere-Joan Cardona, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fundació Institut Germans Trias i Pujol</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cristina Vilaplana, MD</last_name>
    <phone>+3493497861</phone>
    <email>cvilaplana@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Pere-Joan Cardona, MD, PhD</last_name>
    <phone>+34934978686</phone>
    <email>pjcardona.igtp.germanstrias@gencat.cat</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Fundació Institut Germans Trias i Pujol</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Cristina Vilaplana, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Cardona PJ. A dynamic reinfection hypothesis of latent tuberculosis infection. Infection. 2009 Apr;37(2):80-6. doi: 10.1007/s15010-008-8087-y. Epub 2009 Mar 23. Review.</citation>
    <PMID>19308318</PMID>
  </reference>
  <reference>
    <citation>Cáceres N, Tapia G, Ojanguren I, Altare F, Gil O, Pinto S, Vilaplana C, Cardona PJ. Evolution of foamy macrophages in the pulmonary granulomas of experimental tuberculosis models. Tuberculosis (Edinb). 2009 Mar;89(2):175-82. doi: 10.1016/j.tube.2008.11.001. Epub 2008 Dec 24.</citation>
    <PMID>19110471</PMID>
  </reference>
  <reference>
    <citation>Cardona PJ. New insights on the nature of latent tuberculosis infection and its treatment. Inflamm Allergy Drug Targets. 2007 Mar;6(1):27-39. Review.</citation>
    <PMID>17352686</PMID>
  </reference>
  <reference>
    <citation>Mack U, Migliori GB, Sester M, Rieder HL, Ehlers S, Goletti D, Bossink A, Magdorf K, Hölscher C, Kampmann B, Arend SM, Detjen A, Bothamley G, Zellweger JP, Milburn H, Diel R, Ravn P, Cobelens F, Cardona PJ, Kan B, Solovic I, Duarte R, Cirillo DM; C. Lange; TBNET. LTBI: latent tuberculosis infection or lasting immune responses to M. tuberculosis? A TBNET consensus statement. Eur Respir J. 2009 May;33(5):956-73. doi: 10.1183/09031936.00120908.</citation>
    <PMID>19407047</PMID>
  </reference>
  <verification_date>November 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 19, 2009</study_first_submitted>
  <study_first_submitted_qc>May 19, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 21, 2009</study_first_posted>
  <last_update_submitted>July 8, 2011</last_update_submitted>
  <last_update_submitted_qc>July 8, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 11, 2011</last_update_posted>
  <responsible_party>
    <name_title>Dr. Pere-Joan Cardona</name_title>
    <organization>Experimental Tuberculosis Unit. Fundació Institut Germans Trias i Pujol</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Latent Tuberculosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

